Applying nanomedicine in maladaptive inflammation and angiogenesis

Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder

doi:10.1016/j.addr.2017.05.009

Applying nanomedicine in maladaptive inflammation and angiogenesis

Adv Drug Deliv Rev. 2017 Sep 15:119:143-158. doi: 10.1016/j.addr.2017.05.009. Epub 2017 May 12.

Authors

Amr Alaarg¹, Carlos Pérez-Medina², Josbert M Metselaar³, Matthias Nahrendorf⁴, Zahi A Fayad², Gert Storm⁵, Willem J M Mulder⁶

Affiliations

¹ Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, The Netherlands.
² Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
³ Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Institute for Experimental Molecular Imaging, University Clinic, Helmholtz Institute for Biomedical Engineering, Aachen, Germany.
⁴ Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
⁵ Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, The Netherlands.
⁶ Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: willem.mulder@mssm.edu.

Abstract

Inflammation and angiogenesis drive the development and progression of multiple devastating diseases such as atherosclerosis, cancer, rheumatoid arthritis, and inflammatory bowel disease. Though these diseases have very different phenotypic consequences, they possess several common pathophysiological features in which monocyte recruitment, macrophage polarization, and enhanced vascular permeability play critical roles. Thus, developing rational targeting strategies tailored to the different stages of the journey of monocytes, from bone marrow to local lesions, and their extravasation from the vasculature in diseased tissues will advance nanomedicine. The integration of in vivo imaging uniquely allows studying nanoparticle kinetics, accumulation, clearance, and biological activity, at levels ranging from subcellular to an entire organism, and will shed light on the fate of intravenously administered nanomedicines. We anticipate that convergence of nanomedicines, biomedical engineering, and life sciences will help to advance clinically relevant therapeutics and diagnostic agents for patients with chronic inflammatory diseases.

Keywords: Angiogenesis; Atherosclerosis; Cancer; Chronic inflammation; Immunomodulation; Macrophages; Molecular imaging; Monocytes; Nanomedicine; Targeted drug delivery.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Drug Delivery Systems
Humans
Inflammation / drug therapy*
Nanomedicine / methods
Nanoparticles / administration & dosage*
Neovascularization, Pathologic / drug therapy*

Abstract

Publication types

MeSH terms

Grants and funding